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ABSTRACT  
Purpose: Nocturia (waking from sleep at night to void) is a common cause of sleep 
disruption and associated with increased comorbidity and impaired quality of life. 
However, its impact on mortality remains unclear. We performed a systematic review 
and meta-analysis to evaluate the association of nocturia with mortality, both as a 
prognostic and causal risk factor. 
Materials and Methods: We searched PubMed, Scopus, CINAHL and major 
conference abstracts up to December 31, 2018. Random effects meta-analyses addressed 
adjusted relative risks (RR) of mortality for people with nocturia and a meta-regression 
explored potential determinants of heterogeneity, including risk of bias. We applied the 
GRADE framework to rate the quality of evidence for nocturia as a prognostic risk 
factor for mortality and, separately, as a cause of mortality. 
Results: Of 5230 identified reports, 11 observational studies proved eligible. For the 
assessment of nocturia, ten studies used symptom questionnaires and one frequency-
volume charts. Nocturia was defined as ≥2 episodes/night in six (55%), and as ≥3 
episodes/night in five (45%) studies. Pooled estimates demonstrated a risk ratio of 1.27 
(95% confidence interval 1.16-1.40; I2=48%; absolute 5-year mortality difference 1.6% 
and 4.0% in people aged 60 and 75 years, respectively). The pooled estimates of relative 
risk did not differ significantly across varying age, gender, follow-up time, nocturia case 
definition, risk of bias, or study region. We rated the quality of evidence for nocturia as 
a prognostic factor as moderate and as a cause of mortality as very low. 
Conclusions: Nocturia is probably associated with an approximately 1.3-fold increased 
risk of death.  
 
Keywords: epidemiology; meta-analysis; mortality; nocturia; systematic review 
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INTRODUCTION 
Nocturia (waking from sleep at night to void) is one of the most common and 
bothersome lower urinary tract symptoms (LUTS) [1,2]. The incidence of nocturia 
increases markedly with age in both women and men [3]. Besides being a common 
cause of sleep disruption and impaired quality of life, nocturia is associated with 
comorbidities such as diabetes, cardiovascular diseases, chronic respiratory diseases, 
neurological diseases and malignancies [4-6]. An accompanying meta-analysis 
demonstrates that nocturia is associated with a 1.2-fold risk of falls and 1.3-fold risk of 
fractures [7]. Suggesting a number of possible causal pathways, some authors have 
postulated that nocturia may increase the risk of death [8]. 
 
As people with nocturia tend to be older and are more likely to have comorbid 
conditions, the relevance of using nocturia as a mortality risk factor must consider the 
effect of various confounders of the association between nocturia and mortality (i.e. we 
would not want to attribute to nocturia an association with death that can be completely 
explained by older age). To optimally assess the impact of nocturia on mortality, one 
must also take into account fluctuation of nocturia, as well as follow-up time (time 
interval after initial assessment) [3]. Furthermore, investigators should use a validated 
nocturia assessment method, and to further minimize the risk of bias, reliably register all 
deaths during follow-up.  
 
The primary aim of our systematic review and meta-analysis is to clarify the association 
with, and the possible impact of nocturia on mortality, addressing possible effect 
modification by age, gender, follow-up time, varying nocturia definitions, and different 
sources of bias on the relative measures of association (i.e. possible variation in the 
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extent of association by age, gender, and other factors). We therefore tested the relation 
of nocturia with mortality, both as a prognostic risk factor and causal agent. 
 
MATERIALS AND METHODS 
We registered the review protocol (PROSPERO: CRD42016051132), and followed the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidance [9].  
 
Data sources and searches 
We searched the databases of PubMed (from 1946), Scopus (from 1995), and 
Cumulative Index of Nursing and Allied Health Literature (CINAHL) (from 1960) up to 
December 31, 2018. Additionally, we searched the conference proceedings of the 
American Urological Association (AUA), European Association of Urology (EAU), 
International Continence Society (ICS), and International Urogynecological Association 
(IUGA) annual conferences from 2005 to 2018 for any ongoing or unpublished studies. 
We did not apply any restrictions to language or publication status. Finally, we hand-
searched the reference lists of the included articles. Supplementary Appendix 1 provides 
the search strategy. 
 
Eligibility criteria 
We included longitudinal studies with a follow-up (study duration) of at least three 
months with at least 95% of the participants being adults (aged ≥18 years), assessing 
nocturia at baseline and reporting death during follow-up (after an initial assessment). 
We excluded studies that evaluated the effect of any intervention, including cohorts of 
untreated control arms.  
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Study selection and data extraction 
We employed standardized, pilot-tested forms with detailed instructions for screening of 
abstracts and full texts, risk of bias assessments, and data extraction. Pairs of two 
reviewers independently screened study reports for eligibility, assessed risk of bias of 
eligible studies, and abstracted data. The reviewers resolved disagreements through 
discussion and, if necessary, consulted clinician-methodologist adjudicators. When more 
than one report provided data of the same study, we extracted relevant data from all 
reports after excluding overlap. We recorded the country/source of the study sample, age 
and sex distribution, exclusion criteria, assessment tools used for nocturia, follow-up 
time, sample size, exclusion criteria and response rate, and adjustment variables (for the 
mortality effect estimates). We contacted the authors of primary studies for confirmation 
and clarification of our data extraction. 
 
Assessment of the quality of evidence and risk of bias 
According to the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) framework, for assessments of prognosis, a body of observational 
studies begins as high-quality evidence. Several categories of limitations may, however, 
reduce evidence quality, including risk of bias, imprecision, inconsistency and 
indirectness [10]. In contrast, in the GRADE approach for studies of interventions, a 
body of observational studies begins as ‘low-quality’ evidence, and may be rated down 
to ‘very low’ by the same limitations as in intervention studies, but may also be rated up 
by factors such as a large effect size or a dose-response gradient [11]. Therefore, in this 
review, which includes only observational studies, the evidence can provide trustworthy 
inferences about prognosis (i.e. is nocturia associated with mortality) but not causation 
(i.e. does nocturia cause an increase in deaths). To formally compare the certainty of the 
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pooled estimates for nocturia both as a prognostic factor (synonymous with risk factor) 
and as a cause of mortality, we assessed the quality of evidence with the GRADE 
framework for both prognostic and intervention research [10,11].  
 
The methods for risk of bias evaluation for longitudinal cohort studies are less 
developed than the methods for randomised controlled trials [12]. Through discussion 
and consensus building, and taking previous literature into account [3, 13-15], we 
developed an instrument to categorise studies as either low or high risk of bias 
(Supplementary Appendix 2). This includes the features of the included studies that 
could potentially bias the estimates: representativeness of the sample to the general 
population, confidence in the assessments of nocturia and mortality, proportion of 
missing data and adjustments for important potential confounders/risk factors of 
mortality.  
 
Data analysis, including statistical analysis 
To calculate the pooled estimates for relative measures of association of nocturia with 
mortality, we extracted hazard ratios (HR), or alternatively relative risks (RR) to be used 
interchangeably with HRs. To minimize confounding, from the reported regression 
models we selected those with maximum adjustments. If a study reported only an odds 
ratio (OR) instead of HR or RR we, acknowledging the high prevalence of nocturia, 
converted the OR into RR using the following formula:  
 RR = OR / (1 – p + (p x OR)) 
in which p represents the baseline risk i.e. the risk of death in people without nocturia at 
the baseline [16]. We calculated the pooled RRs using the DerSimonian–Laird random 
effects inverse variance method. When raw data were available, to take account of the 
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effect of potential confounders including age and comorbidities, we derived adjusted 
RRs from multivariable logistic regression models.  
 
To address the effect of age and the natural history of nocturia on the relative measures 
of association, we stratified the analyses by three age groups (18-49 yr, 50-69 yr and ≥70 
yr).  We adjusted for gender, follow-up time (<10 vs. ≥10 yr), risk of bias and study 
region and examined these variables as possible effect modifiers using chi-square tests. 
We stratified estimates by nocturia status in terms of a binary variable (case definitions 
of ≥2 vs. 0-1; and ≥3 vs. 0-2 voids/night) and a three-value categorical variable (2 vs. 0-
1 and ≥3 vs. 0-1 voids/night), using the latter to explore exposure-response relationship 
of nocturia with mortality. 
 
We complemented our subgroup analyses using chi-square tests with meta-regression 
analysis weighted by the inverse of the variance in a random effects model employing 
pre-specified hypotheses. We examined the following variables as potential sources of 
heterogeneity: (1) gender, (2) age, (3) length of follow-up, (4) nocturia case definition, 
and (5) risk of bias.  We pre-specified hypotheses that the effect of nocturia on mortality 
would be higher for: (1) male vs. female or mixed gender, (2) younger age (<70 vs. ≥70 
yr), (3) shorter follow-up time (<10 vs. ≥10 yr), (4) higher nocturia case definition (≥3 
vs. ≥2 voids/night), and (5) high vs. low risk of bias. We set a threshold of p value less 
than 0.05 as a minimum criterion for a credible subgroup effect. 
 
We report the association of nocturia with mortality in terms of both relative and 
absolute estimates, presenting five-year absolute risks of death among men and women 
aged 60 years and older — an age group commonly affected by nocturia [3]. When 
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calculating the baseline risks, we first estimated the average five-year death rates from 
the reported annual death rates for people aged 55-64 and 75-84 yr in the USA for 2016 
[17]. Then, for the average estimates on the prevalence of nocturia of two or more voids 
per night [18] in desired age groups, we extracted the reported prevalences from studies 
included in a previous comprehensive systematic review [19] (Supplementary Appendix 
3), calculated the 95% confidence intervals (CI) for natural logarithms of prevalences 
per 100 people and pooled the estimates in random-effects meta-analysis 
(Supplementary Fig. 1). Finally, to derive the baseline risks in the absence and presence 
of nocturia, we divided the average death rates in proportions based on the prevalence of 
nocturia and pooled relative risks for the desired age groups. Statistical analyses were 
performed using metan and metareg in Stata 12.1 (StataCorp, College Station, TX, 
USA) [20]. 
 
 
RESULTS 
Literature search and study characteristics 
We screened 5 230 abstracts and retrieved 132 potentially eligible full text reports and 
22 conference abstracts (Fig. 1). Ten original full text articles and one conference 
abstract provided data on nocturia-associated death, including 19 590 men and 14 241 
women with a total follow-up of 297 379 person-years (Table 1) [21-32]. Five (45%) of 
the 11 authors confirmed the accuracy of our data extraction [22,25,27,29,31]; two 
(18%) corrected some errors or provided additional information [26,32] and four (36%) 
were unable respond to our requests for data checks and clarifications [21,23,28,30]. 
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Studies were conducted on three continents, in male and mixed gender populations that 
varied widely in their age distributions and follow-up times (Table 1). Nocturia was 
defined as ≥2 episodes per night in six (55%), and as ≥3 episodes per night in five (45%) 
studies. Reflecting the differences in study populations, as well as variations in symptom 
assessment methods, the baseline prevalence of nocturia in the study populations varied 
widely, with ranges of 8-34% based on a case definition of ≥2 (vs. 0-1 voids/night) and 
2.5-35% with a case definition of ≥3 (vs. 0-2 voids/night) in adults aged <70 yr; in 
adults aged ≥70 yr, the range was 35-49% in the broader case definition and 8-38% in 
the more restrictive (Supplementary Table 1). 
 
Risk of bias 
To identify eligible individuals, two studies used electoral rolls [22,27], two household 
registries [23,26] and three civil registries [25,29,32]. One study used a combination of 
hospital and primary care registries [28], one recruited patients from a hospital’s 
diabetes clinic [30] and one used primary care registries for White and zip code lists for 
Black participants [31]. We considered the cohorts of seven studies to adequately 
represent general populations with a satisfactory participation rate [21-23,26-28,32] 
(Fig. 2, Table 1). For assessment of nocturia at baseline, ten studies used symptom 
questionnaires and one used frequency-volume charts. We considered eight studies 
(73%) to have assessed nocturia accurately [25-32] (Fig. 2, Table 1). Five studies (45%) 
collected mortality data from a national death registry, and five (45%) used linkage to 
registries of different health care institutions. We considered that ten studies (91%) 
assessed mortality accurately through registry data [21-23,25-30,32]. Eight studies 
(73%) had little missing data [22,25-29,31,32]. Six studies (55%) adequately performed 
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adjustments for their estimates [22,25,26,29,31,32] (Fig. 2, Table 1, Supplementary 
Table 1).   
 
Impact of nocturia on mortality 
The pooled relative risk of death in 11 studies (2 low and 9 high risk of bias) proved 
higher in people with nocturia compared to those without nocturia (RR 1.27; 95% CI 
1.16-1.40; heterogeneity: I2=48.3%; moderate quality evidence for prognosis and very 
low quality evidence for causality) (Fig. 3, Table 2).  
 
In subgroup meta-analyses, the pooled estimates for association between nocturia and 
mortality did not differ significantly for samples stratified by age, gender, follow-up 
time, nocturia case definition, risk of bias, or study region (Supplementary Tables 1-3). 
This was also true for the multivariable-adjusted meta-regression analyses 
(Supplementary Table 4).   
 
Based on the mean death rates in the USA among people aged 60 and 75 yr with 
respective age-specific prevalences of nocturia (≥2 episodes per night) of approximately 
20% and 40% (Supplementary Fig. 1), the nocturia-associated increase in the overall 
five-year absolute death risk were 1.6% and 4.0% among people aged 60 and 75 yr, 
respectively (Fig. 4, Supplementary Fig. 2). 
 
The quality of evidence 
We identified 11 studies: 2 low and 9 high risk of bias (Figure 2). We rated down the 
quality due to the high risk of bias (to which the majority of the included studies were 
susceptible). We therefore rated the quality of evidence (certainty in estimates) as 
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moderate for nocturia as a prognostic risk factor for mortality, and as very low quality 
for nocturia as a causal factor for mortality (Table 2). 
 
DISCUSSION 
This meta-analysis showed a 27% increase in relative risk of death in people with 
nocturia (defined as either ≥2 or ≥3 episodes/night) compared to those without nocturia 
after adjustment for age, gender and various comorbidities. This correspondents with 
nocturia-associated increase in the overall five-year absolute death risk by 1.6% among 
aged 60 yr and 4.0% among aged 75 yr. The magnitude of the association did not differ 
across a number of predictor variables. Our finding is of moderate-quality evidence for 
nocturia as prognostic factor of increased risk of death but only very low-quality 
evidence for nocturia as a cause of mortality.  
 
Strengths and limitations 
The strengths of this review include a comprehensive search of both published and 
unpublished studies without language restrictions; duplicate assessment of eligibility, 
risk of bias, and data extraction; checking of data accuracy with the authors of the 
original studies; and appraisal of the quality of evidence using the GRADE approach for 
inferences regarding nocturia both as a prognostic factor and as a causal factor for 
mortality. Besides the novel approaches in establishing the best available evidence on 
the topic, to our knowledge, our study is the first to provide absolute effects in addition 
to relative estimates on the association between nocturia and mortality (for this purpose, 
we also meta-analyzed the prevalence of nocturia; this information is likely of interest 
itself, see Supplementary Figure 3). 
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The limitations of our review are largely those of the eligible studies. No study was free 
of risk of bias and limitations related to non-representativeness of source populations, 
inaccuracy in assessments of nocturia or mortality, missing data or inadequately adjusted 
analyses were common (Figure 2). Second, although the analyses showed no effect for 
nocturia case definition, only three studies provided estimates for nocturia as a discrete 
variable with multiple values (number of voids). Third, only one study [26], provided 
data on the association between nocturia and mortality specifically for women. Fourth, 
none of the studies addressed causes of death; and we were therefore unable to assess 
mortality from specific causes. Fifth, no detailed data from bladder diaries were 
available, and we were therefore unable to differentiate the effects of nocturia on 
mortality when appearing as an isolated symptom or accompanied by other LUTS, or if 
nocturia was due to global/nocturnal polyuria, reduced bladder capacity or mixed 
etiology [1]. Sixth, there was paucity of studies assessing sleep disorders as potential 
comorbid conditions with nocturia, and thus, we were unable to differentiate between 
the roles of insomnia symptoms as potential confounders vs. mediators for mortality 
(nocturia caused by primary insomnia vs. insomnia secondary to nocturia) [33]. Given 
that, especially among the older people, nocturia is one of the leading causes of sleep 
disruption, which has further been shown to prognosticate mortality, analyses to test 
effect modification by sleep disorders would be highly relevant [34-36]. Accordingly, in 
the two available studies exploring the role of sleep disruption as one of the potential 
mediators between nocturia and mortality, both conducted in Western male populations 
and the other excluded from our review for being an interventional study (a randomized 
trial of dutasteride for prostate cancer chemoprevention), the association between 
nocturia and mortality turned non-significant after controlling the estimates for sleep 
disorders and other comorbidities [31,36]. Seventh, none of the studies utilized more 
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sophisticated analytical techniques, such as structural equation modeling, to identify 
potential causal pathways between nocturia and mortality [37]. Eighth, although the 
meta-regression analysis failed to show an influence of duration of follow-up, lack of 
repeated assessments during the follow-up and, therefore, failure to take into account the 
effect of incident and remittent nocturia on the estimates limits that analysis. Finally, 
results provide only very low-quality evidence regarding nocturia as a cause of the 
increased death rate associated with the exposure. 
 
Relation to prior work  
Only one earlier systematic review with meta-analysis has been published examining the 
impact of nocturia on mortality [38]. This systematic review published in 2015, reported 
a pooled HR of 1.23 (1.07-1.42), comparable to our best estimate. The review included 
seven studies, all included in our review [18,19,22,23,24-26], but failed to include four 
studies that proved eligible in our systematic review: one full text article [30] and one 
conference abstract [23] that were reported before the publication of their review and 
apparently met their eligibility criteria, and two studies that were published after their 
review appeared [31,32]. In their subgroup analyses (no adjustments used or meta-
regression performed), shorter follow-up time (<10 yr vs. >10 yr), larger sample size 
(>5000 vs. <5000 people) and more restrictive nocturia case definition (≥3 vs. ≥2 voids 
per night) predicted mortality. With comprehensive adjustments and inclusion of four 
additional studies [23,30,31,32], none of these subgroup effects remained significant in 
our meta-analysis. To rate the risk of bias, the authors reported that they used or planned 
to use an instrument designed for observational studies [39]; they did not, however, 
present the results. The review also lacked any assessment of nocturia-associated 
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absolute effects on mortality and included no assessment of quality of evidence for 
prognosis or causation.  
 
Implications of findings 
Clinicians and patients should be aware that nocturia occurring at least twice per night 
may be a marker of ill health. Although urological treatments have potential to improve 
quality of life of patients with nocturia, clinicians should focus not only on treating the 
symptom, but also exploring patients’ general health taking into account the relevant 
risk factors for each individual [40,41]. The association between nocturia and mortality 
likely reflects chronic illness as a cause of both nocturia and mortality. For instance, it is 
not difficult to imagine how diabetes could cause both nocturia and premature death.  It 
is less likely, but still possible, that nocturia is in the causal pathway leading to 
premature death. For instance, impaired sleep as a result of nocturia could impair 
physiological night-time blood pressure dipping, increase sympathetic activity [42], and 
thus increase cardiovascular deaths. In addition, fractures and other injuries may result 
from falls or other accidents related to frequent night-time toileting and daytime fatigue 
[7], and complications of these events could result in premature death. Indeed, the 
companion review to this article documents an association between nocturia and falls 
and fractures. These causal pathways are, however, speculative, and we have concluded 
that there is only very low-quality evidence supporting nocturia as a causal factor in 
premature death [7].   
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CONCLUSIONS 
Moderate-quality evidence suggests that nocturia (defined as either ≥2 or ≥3 
episodes/night) is associated with a 1.3-fold increased risk of death. Future 
investigations should address the impact of treatment for nocturia on mortality. 
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Figure (and supplementary material) legends 
Table 1. Characteristics of the original studies included in analyses. 
Table 2. Evidence profile: nocturia as a prognostic factor for mortality versus as a cause 
of mortality. 
Figure 1. Study flow chart. 
Figure 2. Risk of bias of the included studies. 
Figure 3. A forest plot of the relative risks of death in people with nocturia. 
Figure 4. Relative and absolute risk of death in five years between people with and 
without nocturia. 
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 Study Country Source of sample Population characteristics Exclusion criteria Assessment of 
nocturia 
Assessment of 
mortality 
Median 
follow-up 
time  
No. of 
contacted at 
the baseline 
No. of eligible 
respondents  
Asplund 
1999 [21] 
Sweden Pensioners' 
association registry 
Both sex, 40% men, mean 
age 73 yr (range 53-92 yr)a 
None Unvalidated  National death 
registry 
4.5 yr 10216 6143 (60%) 
Bursztyn 
2006 [22] 
Israel Electoral records Both sex, 55% men, all 
aged 70 yr  
None Unvalidated  National death 
registry 
12 yr 759 456 (60%) 
Fitzgerald  
2009 [23,24]b 
Puerto Rico Various public 
registries 
Men, mean age 71 yr 
(range 60-99 yr) 
Institutionalized Unvalidated  National death 
registry 
2 yr 1736 1480 (85%) 
Nakagawa 
2010 [25] 
Japan Civil registry Both sex, 46% men, mean 
age 76 yr (range 70-97 yr) 
Non-members of NHI 
system 
In accordance with 
IPSS/AUA-SI 
NHI registry 5 yr 2925 784 (27%) 
Kupelian 2011 
[26] 
USA Various public 
registries 
 
Both sex, 47% men, mean 
age 49 yr (range 20-90 yr) 
Institutionalized In accordance with 
IPSS/AUA-SI 
NHCS Linked 
Mortality Files 
8.8 yr 39695 15988 (69%) 
Galizia 
2012 [27] 
Italy Electoral rolls 
 
Both sex, 45% men, mean 
age 74 yr (range 65+ yr) 
None In accordance with 
IPSS/AUA-SI 
GP registries, 
death certificates 
12 yr 1780 1288 (72%) 
Lightner 2012 
[28] 
USA Medical records 
from various health 
care units 
Men, mean age 54 yr 
(range 40-79 yr) 
Surgery/condition 
affecting lower urinary 
tract 
AUA-SI (assessed 
every 2 yrs) 
Multiple sources 
incl. death 
certificates and 
autopsy reports 
17 yr 3874 2115 (55%)c 
Van Doorn 
2012 [29] 
The 
Netherlands 
Civil registry Men, mean age 61 yr 
(range 50-78 yr) 
Surgery/condition 
affecting lower urinary 
tract, poor health 
FVC (frequency-
volume chart) 
GP registries 13.4 yr 3398 1114 (33%) 
Chung 
2014 [30] 
Taiwan Hospital diabetic 
clinic 
Both sex, 52% men, mean 
age 63 yr (range 32-94 yr)a 
Treatment for type 2 
diabetes for less than 1 
yr 
OABSS National death 
registry 
2.5 yr 1715 1301 (76%) 
Endeshaw 
2016 [31] 
USA Medicare 
beneficiares, 
designated zip code 
areas 
Men, mean age 74 yr 
(range 70-79 yr) 
None IPSS Clinic visits, 
telephone 
contacts, death 
certificates 
9 yr 
 
Unclear 1478 
Åkerla 
2019 [32] 
Finland Civil registry 
 
Men, mean age 58 yr 
(range 50-70 yr) 
None  DAN-PSS 
(assessed every 
five years) 
National death 
registry 
21 yr 3143 1332 (42%)d 
AUA-SI = American Urological Association Symptom Index, DAN-PSS = Danish Prostatic Symptom Score, GP = general practice, IPSS = International Prostate Symptom Score, 
LUTS = lower urinary tract symptoms, NHCS = National Center for Health Statistics, NHI = National Health Insurance, OABSS = Overactive Bladder Symptom Score 
a Age range approximated by using the reported standard deviation (SD) for mean age (mean age ± 3SD). 
b Previously unpublished analyses based on the study raw data [21].  
c To replace men who either died or dropped out, additional 332 men were recruited during the first four years of follow-up. 
d
 Response available for every assessment of LUTS (while alive). 
  
Table 1. Characteristics of the original studies included in analyses. 
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  Summary of findings Quality assessment 
No. of participantsa 
No. of 
studies 
(design) No nocturia Nocturia 
Relative risk 
(95% CI) 
Absolute risk 
difference 
Prognosis vs. 
causationb Starting 
quality 
Risk of 
biasc 
Inconsis-
tency Indirectness Imprecision 
Certainty in 
estimates 
Prognosis High Serious limitations 
No serious 
limitations 
No serious 
limitations 
No serious 
limitations Moderate 
11 
(observation
al cohort) 
26763 7048 1.27 (1.16-1.40) c 
Age 60 yr: 
1.6% per 5 yr 
Age 75 yr: 
4% per 5 yr 
Causation Low Serious limitations 
No serious 
limitations 
No serious 
limitations 
No serious 
limitations Very low 
GRADE = Grades of Recommendation, Assessment, Development, and Evaluation 
a
 Some studies reported the number of exposed participants for several nocturia case definitions. In these cases, the number of participants with ≥ 2 and 0-1 voids/night was 
included in the total count of exposed and unexposed participants. 
b
 Assessment based on the principles of the GRADE framework where the body of observational evidence begins as high quality when used for prognosis research and as low 
quality when used for intervention research.  
c Assessment described in Supplementary Appendix 2 and Fig. 2. 
 
Table 2. Evidence profile: nocturia as a prognostic factor for mortality versus as a cause of mortality. 
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